Gonorrhea treatment guidelines in Canada: 2004 Update

CMAJ. Canadian Medical Association Journal

Volumn 171, Issue 11, 2004, Pages 1345-1346

  Mann, Janice ^a   Kropp, Rhonda ^a   Wong, Tom ^a   Venue, Sylvie ^b   Romanowski, Barbara ^c  

^a PUBLIC HEALTH AGENCY OF CANADA   (Canada)

^b Gouvernement du Quebec   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ANTIEMETIC AGENT; AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; CIPROFLOXACIN; DILUENT; LIDOCAINE; OFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPECTINOMYCIN; TETRACYCLINE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTHROPATHY; CANADA; DRUG SURVEILLANCE PROGRAM; GASTROINTESTINAL SYMPTOM; GONORRHEA; HUMAN; MEDICAL INFORMATICS; NEISSERIA GONORRHOEAE; PRACTICE GUIDELINE; PREVENTIVE MEDICINE; REVIEW; SINGLE DRUG DOSE;

EID: 9644259110     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.045088     Document Type: Review

References (3)

1. Sarwal S, Wong T, Sevigny C, Ng LK. Increasing incidence of ciprofloxacin-resistant Neisseria gonorrhoeae infection in Canada. CMAJ 2003;168(7):872-3.
2. Ng LK, Sawatzky P, Martin IE, Booth S. Characterization of ciprofloxacin resistance in Neisseria gonorrhoeae isolates in Canada. Sex Trans Dis 2002;29(12):780-8.
3. Increases in fluoroquinolone-resistant Neisseria gonorrhoeae among men who have sex with men - United States, 2003, and revised recommendations for gonorrhea treatment, 2004. MMWR Mort Mortal Wkly Rep 2004; 53(16):335-8.